A groundbreaking study shows that introducing peanut products to infants can lower the risk of developing peanut allergies by 43%. Discover how this could change pediatric dietary guidelines!
A groundbreaking study shows that introducing peanuts to babies as early as 4 months can significantly reduce the risk of developing allergies. Health experts report a major decline in peanut allergy prevalence since revised guidelines were implemented.
A new Washington Post-KFF poll reveals pediatricians are the most trusted source for vaccine information, with parents' confidence significantly influencing vaccination rates. Discover the impact of misinformation on parental decisions.
In a groundbreaking study, researchers found that permethrin-treated baby wraps could reduce malaria cases in young children by 65%. This innovative approach may provide a new line of defense against the deadly disease in sub-Saharan Africa.
A groundbreaking study shows that pediatricians using simple tools like training videos and health record prompts can significantly reduce peanut allergy rates in children by up to 80%. Find out how early introduction of peanuts can protect your child!
A school-aged child in Los Angeles County has died from a rare complication linked to a past measles infection. Health officials stress the importance of vaccinations to prevent such tragedies.
A heartbreaking case in Los Angeles underscores the critical importance of vaccinations after a school-age child dies from a rare measles-related complication years after recovering from the illness.
The Trump administration's latest health report aims to combat chronic diseases among children, but experts question its lack of actionable details and highlight concerning disconnects in policy execution.
A new monoclonal antibody called clesrovimab has been recommended for infants to prevent RSV, stirring debate among health experts and advocates. The FDA approved the treatment just weeks ago.
In a pivotal vote, the CDC's advisory committee has recommended the use of clesrovimab, a new monoclonal antibody, for infants under eight months to combat RSV, marking a significant advancement in public health.
